EU Medicines Agency Reverses Course on Eli Lilly's Alzheimer Drug
Summary by EURACTIV
3 Articles
3 Articles
The European Medicines Agency (EMA) is changing its mind and is now recommending that the EU Commission approve the drug Kisunla for early Alzheimer's disease, reports Läkartidningen.
·Stockholm, Sweden
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left1Leaning Right1Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium